

- a4
Contd
22. A solid oral dosage form according to claim 10 comprising 20 to 360 mg of valsartan.
23. A solid oral dosage form according to claim 11 comprising 20 to 360 mg of valsartan.
24. A solid oral dosage form according to claim 8 comprising less than 13% of crosopvidone.
-

STATUS OF THE CLAIMS

Claims 1-14 were present in the application.

Claims 1-6 have been deleted.

Claims 15-24 have been added.

Claims 7-24 are presented for consideration.


REMARKS

This Preliminary Amendment is presented to add a parental data paragraph, to claim subject matter restricted from the parental application and to add additional claims which more completely define Applicants invention.

Attached hereto is a marked-up version of the changes made to the claims by the current amendment. The attached page is captioned "Version with markings to show changes made."

Respectfully submitted,

Novartis Corporation
Patent and Trademark Dept.
564 Morris Avenue
Summit, NJ 07901-1027
(908) 522-6923
Date: February 6, 2002



Gregory D. Ferraro
Attorney for Applicants
Reg. No. 36,134

Amend the following claims:

9. (Amended) A solid oral dosage form according to claim 7 [or 8] comprising less than 13% of crospovidone.
11. (Amended) A solid oral dosage form according to [any one of claims 7 to 10] claim 7 comprising 20 to 65% of valsartan.
12. (Amended) A solid oral dosage form according to [any one of claims 7 to 11] claim 7 comprising 20 to 360 mg of valsartan.